You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.

Open menu


BMS advances AI-designed drug candidate into development

Bristol Myers Squibb (BMS) is to in-license an immune-modulating drug candidate created by artificial intelligence(AI)-driven pharmatech Exscientia.